A Partneringreview 2006 – Therapy area chapter provides an in depth view into the area of your interest. The chapter focus on deals and alliances announced in 2005, and the information is presented in a clear and accessible format.
The report analyzes deals announced by company, industry focus, and development stage. Every deal is fully categorized, and includes financials such as headline value, upfront and milestone payments, where disclosed.
Each deal is annotated with a deal number, such as #43. This number links to the full deal in the deal listing at the rear of each report. When using the PDF format in Acrobat Reader, simply click on the number to move around the report.
Other selected research from the 'Business Development' category:
Partneringdesk Dainippon Sumitomo Pharma& Company Deals Briefing
Comprehensive summary of the last 5 years of deal-making by the industry’s top 50 pharmaceutical and biotech companies. Learn More
Partneringreview 2006 - Company deal index (volume 1)
Other selected research from the 'Dermatology' category:
The World Dermatological Market Analysis & Forecasts 2007-2022
This report predicts that the retail market for dermatological treatments will continue to show significant growth for what is an already large market. Corticosteroid agents will still be the main sales drivers to dermatological market whilst botulinum toxin and other cosmetic treatments will be more significant during the forecast period. Learn More
The World Dermatological Market Outlook 2010-2024
Where will the main commercial opportunities lie in the treatment of skin disorders? Our new pharma market report explains Learn More
Other selected research from the 'Oncology' category:
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 207 companies plus partners who are today developing 264 Alpha6Beta4 integrin pathway targeting drugs in 848 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 125 drugs where development has been ceased. Learn More
Hematological Cancers - A Therapeutic & Competitive Insight
BioSeeker Group has studied the progress of 125 of the most prominent drugs in development for the treatment of hematological cancers. This extensive 190+ pages report not only describes and analyzes the latest years of progress in lymphoma and leukemia, it also provides an insight and framework to understand this complex field. Learn More
Other selected research from the 'Reproduction' category:
HRT: Major Milestones - Current Perspectives on HRT and Menopause
The HRT market peaked in 2001 at $3.5 billion across the seven major markets. The Women`s Health Initiative findings released in 2002 showing that HRT use was associated with an increased breast cancer and cardiovascular disease risk precipitated a major decline in HRT use and sales. This report identifies the impact this trial has had on HRT prescribing and looks at efforts to reposition HRT. Learn More
Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmission
Sexually transmitted diseases (STDs) represent a significant health threat given their potentially serious complications and association with increased transmission of human immunodeficiency virus (HIV). High disease burdens, low diagnosis and... Learn More
Other selected research from the 'Other' category:
Financial Markets Research: Palatin Technologies’ Bremelanotide - Competition and regulatory risk cloud potential
Palatin Technologies’ bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD). Learn More
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
This report provides analysis of the commercial and clinical potential of non-hormonal treatments for menopausal symptoms based on seven key opinion leader interviews, with focus on the treatment of vasomotor symptoms. Learn More